Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 18-Month Safety and Efficacy Study of Leuco-methylthioninium bis(hydromethanesulfonate) TRx0237 in Subjects With Mild Alzheimer's Disease.

Trial Profile

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 18-Month Safety and Efficacy Study of Leuco-methylthioninium bis(hydromethanesulfonate) TRx0237 in Subjects With Mild Alzheimer's Disease.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Nov 2017

At a glance

  • Drugs TRx 0237 (Primary)
  • Indications Alzheimer's disease; Dementia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors TauRx Therapeutics
  • Most Recent Events

    • 27 Nov 2017 Primary endpoint has been met. (Change from Baseline in Alzheimers Disease Cooperative Study - Activities of Daily Living (ADCS-ADL23)), as reported in a TauRx Therapeutics media release.
    • 27 Nov 2017 Primary endpoint has been met. (Change from Baseline in Alzheimers Disease Assessment Scale - Cognitive Subscale (ADAS-cog11)), as reported in a TauRx Therapeutics media release.
    • 27 Nov 2017 According to a TauRx Pharmaceuticals media release, Gordon Wilcock is a lead author of this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top